"and other jabs" - and yet weirdly Pfizer didn't suffer from confusing and contradictory statements on its efficacy because it wasn't the Russians who screwed up the dosing strategy in one section of the Phase III trial, leading to the fortuitous discovery of a more efficacious dosing regime which then wasn't the actual dosing regime recommended to the public anyway. And it wasn't the Russians who decided not to test the vaccine on older people at first i.e. those who need it most (idk maybe it would have made the efficacy look worse or something) so that in Europe, where we weren't nationalistically invested in it, we couldn't give it to older people, so then instead it caused reactions in younger people, so we had to stop while they said there wasn't a link to the vaccine oh wait yes there is, so now we can only give it to older people, except they don't want it because they (correctly) think it's less effective, and anyway it doesn't matter because they've not even supplied 40% of what they said they'd make their "best effort" to supply to the EU.So much has gone wrong, and the well-intentioned folk at Oxford and AstraZeneca have taken so many blows, that it is hardly surprising that they wonder whether they have been the victims of a deliberate disinformation campaign.
It seems they have. There is clear evidence that the Oxford vaccine, and other jabs, have been targeted by Russians peddling disinformation in order to promote their own version, Sputnik V.
Oh and it may reduce transmission by two thirds is slightly effective maybe against asymptomatic covid.
Meanwhile the UK which has relied heavily on the AstraZeneca vaccine, getting it from India instead of letting the Indians vaccinate themselves with it, is now having 16,000 cases a day of the variant from India. Still, good that the UK got priority, thanks to getting AstraZeneca to make it instead of Merck.
So, yeah, all the Russians' fault.
No, the contractor supplied correctly. In Oxford they re-measured it badly.A contractor accidentally supplied half-doses, according to AstraZeneca’s Sir Mene Pangalos, who headed the research once the company was on board.
Oh and it turns out that you can't just leave out data to make the results look slightly better?